Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

A2A receptor and striatal cellular functions: regulation of gene expression, currents, and synaptic transmission.

Schiffmann SN, Dassesse D, d'Alcantara P, Ledent C, Swillens S, Zoli M.

Neurology. 2003 Dec 9;61(11 Suppl 6):S24-9. Review.

PMID:
14663005
2.

Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson's disease.

Kase H, Aoyama S, Ichimura M, Ikeda K, Ishii A, Kanda T, Koga K, Koike N, Kurokawa M, Kuwana Y, Mori A, Nakamura J, Nonaka H, Ochi M, Saki M, Shimada J, Shindou T, Shiozaki S, Suzuki F, Takeda M, Yanagawa K, Richardson PJ, Jenner P, Bedard P, Borrelli E, Hauser RA, Chase TN; KW-6002 US-001 Study Group.

Neurology. 2003 Dec 9;61(11 Suppl 6):S97-100. Review.

PMID:
14663020
3.

Anatomy of adenosine A2A receptors in brain: morphological substrates for integration of striatal function.

Rosin DL, Hettinger BD, Lee A, Linden J.

Neurology. 2003 Dec 9;61(11 Suppl 6):S12-8. Review.

PMID:
14663003
4.

Translating A2A antagonist KW6002 from animal models to parkinsonian patients.

Chase TN, Bibbiani F, Bara-Jimenez W, Dimitrova T, Oh-Lee JD.

Neurology. 2003 Dec 9;61(11 Suppl 6):S107-11. Review.

PMID:
14663022
5.

Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications.

Morelli M, Di Paolo T, Wardas J, Calon F, Xiao D, Schwarzschild MA.

Prog Neurobiol. 2007 Dec;83(5):293-309. Epub 2007 Jul 27. Review.

PMID:
17826884
6.

Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson's disease.

Fuxe K, Agnati LF, Jacobsen K, Hillion J, Canals M, Torvinen M, Tinner-Staines B, Staines W, Rosin D, Terasmaa A, Popoli P, Leo G, Vergoni V, Lluis C, Ciruela F, Franco R, Ferré S.

Neurology. 2003 Dec 9;61(11 Suppl 6):S19-23. Review.

PMID:
14663004
7.

A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD.

Jenner P.

Neurology. 2003 Dec 9;61(11 Suppl 6):S32-8. Review.

PMID:
14663007
8.

Distribution, biochemistry and function of striatal adenosine A2A receptors.

Svenningsson P, Le Moine C, Fisone G, Fredholm BB.

Prog Neurobiol. 1999 Nov;59(4):355-96. Review.

PMID:
10501634
9.

Adenosine A2A receptor antagonists and Parkinson's disease: state of the art and future directions.

Simola N, Morelli M, Pinna A.

Curr Pharm Des. 2008;14(15):1475-89. Review.

PMID:
18537671
10.

Adenosine-dopamine interactions revealed in knockout mice.

Salmi P, Chergui K, Fredholm BB.

J Mol Neurosci. 2005;26(2-3):239-44. Review.

PMID:
16012197
11.
12.

Adenosine A2A-dopamine D2 receptor-receptor heteromers. Targets for neuro-psychiatric disorders.

Ferré S, Ciruela F, Canals M, Marcellino D, Burgueno J, Casadó V, Hillion J, Torvinen M, Fanelli F, Benedetti Pd Pd, Goldberg SR, Bouvier M, Fuxe K, Agnati LF, Lluis C, Franco R, Woods A.

Parkinsonism Relat Disord. 2004 Jul;10(5):265-71. Review.

PMID:
15196504
13.

Neuroprotection by caffeine and more specific A2A receptor antagonists in animal models of Parkinson's disease.

Schwarzschild MA, Xu K, Oztas E, Petzer JP, Castagnoli K, Castagnoli N Jr, Chen JF.

Neurology. 2003 Dec 9;61(11 Suppl 6):S55-61. Review.

PMID:
14663012
14.
15.

[Neurobiology and pharmacotherapy of social phobia].

Aouizerate B, Martin-Guehl C, Tignol J.

Encephale. 2004 Jul-Aug;30(4):301-13. Review. French.

PMID:
15538306
16.

Targeting adenosine A2A receptors in Parkinson's disease.

Schwarzschild MA, Agnati L, Fuxe K, Chen JF, Morelli M.

Trends Neurosci. 2006 Nov;29(11):647-54. Epub 2006 Oct 9. Review.

PMID:
17030429
17.

Adenosine-dopamine interactions: development of a concept and some comments on therapeutic possibilities.

Fredholm BB, Svenningsson P.

Neurology. 2003 Dec 9;61(11 Suppl 6):S5-9. Review.

PMID:
14663001
18.

Caffeine as a psychomotor stimulant: mechanism of action.

Fisone G, Borgkvist A, Usiello A.

Cell Mol Life Sci. 2004 Apr;61(7-8):857-72. Review.

PMID:
15095008
19.

Striatal metabotropic glutamate receptors as a target for pharmacotherapy in Parkinson's disease.

Bonsi P, Cuomo D, Picconi B, Sciamanna G, Tscherter A, Tolu M, Bernardi G, Calabresi P, Pisani A.

Amino Acids. 2007 Feb;32(2):189-95. Epub 2006 May 22. Review.

PMID:
16715415
20.

Role of giant depolarizing potentials in shaping synaptic currents in the developing hippocampus.

Mohajerani MH, Cherubini E.

Crit Rev Neurobiol. 2006;18(1-2):13-23. Review.

PMID:
17725505

Supplemental Content

Support Center